PMID- 31215251
OWN - NLM
STAT- MEDLINE
DCOM- 20190712
LR  - 20231013
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Print)
IS  - 1354-3784 (Linking)
VI  - 28
IP  - 7
DP  - 2019 Jul
TI  - Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
PG  - 583-592
LID - 10.1080/13543784.2019.1632289 [doi]
AB  - Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all 
      patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. 
      The mammalian target of rapamycin (mTOR) has been identified as a key signaling 
      node enhancing tumor survival and drug resistance in PDAC; hence, it is 
      considered a promising therapeutic target. Areas covered: We comprehensively 
      reviewed the evidence from preclinical and phase I and II clinical trials, based 
      on the authors'clinical experience and a PubMed, Cochrane library, Embase, and 
      Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus 
      has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination 
      with stroma-targeted therapies may be a promising area to explore in clinical 
      trials.
FAU - Babiker, Hani M
AU  - Babiker HM
AD  - a Early Phase Clinical Trials Program , University of Arizona Cancer Center , 
      Tucson , AZ , USA.
FAU - Karass, Michael
AU  - Karass M
AD  - b New York Medical College , Westchester Medical Center , Valhalla , NY , USA.
FAU - Recio-Boiles, Alejandro
AU  - Recio-Boiles A
AD  - a Early Phase Clinical Trials Program , University of Arizona Cancer Center , 
      Tucson , AZ , USA.
FAU - Chandana, Sreenivasa R
AU  - Chandana SR
AD  - c Department of Hematology-Oncology , Phase I Program, START Midwest , Grand 
      Rapids , MI , USA.
FAU - McBride, Ali
AU  - McBride A
AD  - d Department of Pharmacy , University of Arizona Cancer Center , Tucson , AZ , 
      USA.
FAU - Mahadevan, Daruka
AU  - Mahadevan D
AD  - a Early Phase Clinical Trials Program , University of Arizona Cancer Center , 
      Tucson , AZ , USA.
LA  - eng
GR  - P30 CA023074/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20190621
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/pharmacology
MH  - Carcinoma, Pancreatic Ductal/*drug therapy/pathology
MH  - Drug Resistance, Neoplasm
MH  - Everolimus/*administration & dosage/pharmacology
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Survival
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/metabolism
PMC - PMC6681663
MID - NIHMS1532227
OTO - NOTNLM
OT  - Everolimus
OT  - mTOR
OT  - pancreatic adenocarcinoma
EDAT- 2019/06/20 06:00
MHDA- 2019/07/13 06:00
PMCR- 2020/07/01
CRDT- 2019/06/20 06:00
PHST- 2019/06/20 06:00 [pubmed]
PHST- 2019/07/13 06:00 [medline]
PHST- 2019/06/20 06:00 [entrez]
PHST- 2020/07/01 00:00 [pmc-release]
AID - 10.1080/13543784.2019.1632289 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2019 Jul;28(7):583-592. doi: 
      10.1080/13543784.2019.1632289. Epub 2019 Jun 21.